Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:真菌性網脈絡膜炎への抗真菌薬投与終了後に脈絡膜新生血管(CNV)の合併を認めた症例の報告。
症例:患者は77歳,男性。急性膵炎にて加療中にCandida albicansによる真菌血症を発症し,近畿中央病院眼科へ紹介され受診となった。
所見:初診時の視力は右(0.8),左(0.7)であり異常所見はなかったが,1週間後の再診時に真菌性網脈絡膜炎の発症が確認され,抗真菌薬による加療を施行し良好な結果を得られた。抗真菌薬投与終了2か月後に光干渉断層計(OCT)にて真菌性網脈絡膜炎の再発を疑う病変が出現したため,抗真菌薬の投与を再開した。しかし,病変の縮小は得られず,さらに3週間後には囊胞様黄斑浮腫(CME)の合併を認めた。蛍光眼底造影検査およびOCTアンギオグラフィにて病変部にCNVの発生が確認されたためラニビズマブ硝子体内注射(IVR)を施行したところ,病変の縮小とCMEの消失を認めた。初回IVRから7週間後にCMEの再発を認めたため2度目のIVRを施行し,4か月後の現在まで病変の再発はない。
結論:真菌性網脈絡膜炎に伴うCNVの発生に対しては,OCTによる評価が重要であり,抗血管内皮増殖因子(vascular endothelial growth factor:VEGF)治療が有効と考える。
Abstract Purpose:We report a case of choroidal neovascularization(CNV)following fungal retinochoroiditis.
Case:A 77-year-old man developed fungemia due to Candida albicans during treatment for acute pancreatitis and was referred to our department.
Findings and clinical course:At the first visit, visual acuity was 0.8 in the right eye and 0.7 in the left eye and no abnormal findings were observed. However, at the time of re-examination one week later, the onset of fungal retinochoroiditis was confirmed, and treatment with an antifungal drug was initiated. Two months after the end of antifungal administration, a lesion was suspected for recurrence of fungal retinochoroiditis on the optical coherence tomography(OCT). Therefore, we resumed administration of antifungal drug, but no reduction in lesion was obtained. After 3 weeks, complications of cystic macular edema(CME)was observed and CNV was confirmed by fluorescein angiography and OCT angiography, so intravitreal injection of ranibizumab(IVR)was performed and the lesion reduced and CME disappeared. 7 weeks after the first IVR, he underwent a second IVR because of CME recurrence, and he has not seen a recurrence of the lesion until now 4 months later.
Conclusion:For the development of CNV associated with fungal retinochoroiditis, evaluation by OCT is important, and anti-VEGF treatment is considered to be effective.
Copyright © 2022, Igaku-Shoin Ltd. All rights reserved.